|
Chỉ định và Liều dùng
Oral
Hyperlipidaemias Adult: 100 mg daily.
|
||||||
|
Suy thận
|
||||||
|
Suy gan
Severe: Contraindicated.
|
||||||
|
Cách dùng
May be taken with or without food.
|
||||||
|
Chống chỉ định
Severe hepatic and renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Concurrent use w/ other fibrates.
|
||||||
|
Thận trọng
Patient w/ hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity w/ other fibrates. Mild to moderate hepatic and renal impairment.
|
||||||
|
Tác dụng không mong muốn
Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia. Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.
|
||||||
|
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, somnolence, and fatigue, if affected, do not drive or operate machinery.
|
||||||
|
Chỉ số theo dõi
Monitor for renal function. Perform periodic LFT every 3 mth for the 1st yr of treatment. Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.
|
||||||
|
Quá liều
Symptom: Rhabdomyolysis. Management: Symptomatic and supportive treatment. Employ gastric lavage.
|
||||||
|
Tương tác
Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
Potentially Fatal: Increased risk of rhabdomyolysis and myoglobinuria w/ other fibrates. |
||||||
|
Tác dụng
Description:
Mechanism of Action: Ciprofibrate is a fibric acid derivative that has a marked hypolipidaemic action. It reduces both LDL and VLDL cholesterols, leading to reduced levels of triglycerides, while increasing the HDL cholesterol levels. Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: W/in 1-4 hr. Distribution: Plasma protein binding: Approx 98%. Excretion: Via urine (as unchanged drug and glucuronide conjugates). Elimination half-life: Approx 38-86 hr. |
||||||
|
Bảo quản
Store below 25°C.
|
||||||
|
Phân loại MIMS
|
||||||
|
Phân loại ATC
C10AB08 - ciprofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
|
||||||
|
Tài liệu tham khảo
Anon. Ciprofibrate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2016. Buckingham R (ed). Ciprofibrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016. Joint Formulary Committee. Ciprofibrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.
|
Đăng xuất
